Suneva Medical Expands Its Operations to Santa Barbara
Published: Feb 21, 2013
SANTA BARBARA, Calif., Feb. 21, 2013 /PRNewswire/ -- Suneva Medical, Inc., a privately-held aesthetics company, today announced that it has expanded from its San Diego base to open an office in Santa Barbara. The Company has leased office space at 5383 Hollister Avenue to meet the rapidly growing needs of its team.
"Santa Barbara has been home to some important and successful aesthetics companies and has generated a tremendous pool of experienced local professionals. We have made several key hires in finance, marketing, clinical, and regulatory over the past few months and will continue to recruit from the great local talent pool as we grow our business," commented Nick Teti, Chairman and CEO of Suneva Medical.
This move follows several significant corporate developments for Suneva Medical in 2012. The company expanded its portfolio with the acquisitions of two best-in-class topical facial aesthetic products, ReFissa® and ReGenica®, while also completing critical milestones in its long-term 5-year and acne scar indication clinical trials for its dermal filler ArteFill®.
ReFissa is the only .05% tretinoin cream available on the market with a broad FDA approval for treating facial fine lines and wrinkles, mottled hyperpigmentation and tactile roughness. It represents the gold standard in anti-aging tretinoins. ReFissa is formulated in a soothing emollient base specifically suited to hydrating mature skin.
ReGenica Skincare is the latest scientific breakthrough fusing the promise of stem cells with the power of growth factors. The ReGenicaline of products was developed by Dr. Gail K. Naughton, a world-renowned scientist in regenerative medicine. ReGenica contains a highly potent composition of active growth factors and proteins developed through a revolutionary and patented method. The proprietary blend of ingredients in ReGenica have been clinically proven to help reduce the signs of aging and accelerate recovery times after laser treatments. Allure Magazine recently featured ReGenica in its December issue on "Totally Gorgeous Skin" and quoted renowned dermatologist, Dr. Doris Day, who stated "What we've been waiting for is a formula like this one with additional science to back it up. This line may help skin appear more youthful over time."
Suneva Medical also launched a multi-center study to investigate the efficacy of ArteFill, its lasting dermal filler, for the treatment of acne scars. Between two and five million people in the U.S. on an annual basis suffer from acne, with approximately 60%-70% of them going on to experience scarring. There is no product on the market today that is approved for treating this distressing and highly prevalent condition. Suneva worked with the FDA to create a novel classification system to evaluate acne scars and subsequently launched the study with 10 premier clinical investigational sites across the country. Recruitment and enrollment was quickly completed and all study subjects have now received treatment. Efficacy and safety data will be available later this year with plans to submit the PMA Supplement for the new indication by the end of 2013.
About Suneva Medical
Suneva Medical, Inc. is a privately-held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the dermatology and the plastic and cosmetic surgery markets. The Company currently markets ArteFill®, ReFissa® and ReGenica® in the U.S. and Bellafill®in Canada. For more information visit www.sunevamedical.com.
SOURCE Suneva Medical, Inc.